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BACKGROUND
• According to the World Health Organization, two billion people (30% of the 
world’s population) suffer from anemia.1 Iron deficiency is the primary 
causative factor in half of these cases.
• The standard of care for iron deficiency anemia is oral iron 
supplementation as it is safe, effective, well tolerated, and inexpensive.2
• Parenteral iron therapy is more costly and may cause severe side effects, 
such as hypotension and anaphylaxis.3 It is indicated as first line in patients 
who are unable to tolerate or absorb oral preparations, in those with 
unresolved bleeding, in those undergoing dialysis, and in pregnant women.
• Within our hospital system, an algorithm has been proposed to limit the first 
line use of intravenous (IV) iron sucrose (Venofer®) .
OBJECTIVES
1. Determine if patients treated with Venofer® as first line therapy for iron 
replacement met Baptist Health South Florida (BHSF)’s proposed IV iron 
algorithm criteria
2. Assess if patients had hemoglobin, transferrin saturation (TSAT), and 
ferritin levels drawn at baseline
3. Examine potential cost savings associated with proposed algorithm
METHODOLOGY
• This retrospective study was approved by the BHSF Institutional Review 
Board.
• An electronic report of all inpatients who received Venofer® in June 2016 
was generated by our pharmacy systems specialist.
• Patients <18 years old and those who first received oral iron 
supplementation were excluded.
• Of the resultant records, fifty charts were chosen at random to determine if 
they met the following criteria outlined in BHSF’s proposed algorithm:
o Baseline hemoglobin <12 g/dL, TSAT <30%, ferritin <1200 ng/mL




-Patients with gastrointestinal (GI) disorders
-Patients with malabsorption syndromes
-Patients with severe/ongoing blood loss
-Patients who cannot receive oral intake (NPO)










• The criteria outlined in our hospital system’s proposed algorithm can greatly 
streamline the use of parenteral iron therapy.
• Since these implications translate into safe and cost effective treatment, a 
system wide initiative will be implemented to promote the use of oral iron 
supplementation.
DISCUSSION
• Out of 50 patients reviewed, 16 (32%) did not fall into the proposed patient 
types who may receive IV iron first line.
• All patients had a baseline hemoglobin level (100%), 18 (36%) had 
baseline TSAT values, and 23 (46%) had baseline ferritin levels.  
• All baseline hemoglobin levels were <12 g/dL (100%). However, only 17 
patients (34%) had baseline TSAT <30% and only 21 patients (42%) had 
baseline ferritin <1200 ng/mL.
• On average, inappropriate therapy lasted about 2 days.
• Based on our facility’s acquisition cost of $29.61 for one 100 mg vial of 
Venofer®, the cost of inappropriate parenteral therapy totaled $3,168.
• Limitations: Brief study period, small sample size, evaluation of only 
inpatients, and retrospective data collection that depended on what was 
documented in the electronic medical record.
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